OC
AGIO icon

Oppenheimer & Co’s Agios Pharmaceuticals AGIO Stock Holding History

Oppenheimer & Co’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-50,340
Closed -$1.79M – 1256
2020
Q1 		$1.79M Sell
50,340
-200
-0.4% -$9.24K 0.05% 368
2019
Q4 		$2.41M Sell
50,540
-7,335
-13% -$277K 0.06% 359
2019
Q3 		$1.88M Hold
57,875
– – 0.05% 411
2019
Q2 		$2.89M Sell
57,875
-6,252
-10% -$334K 0.08% 291
2019
Q1 		$4.33M Buy
64,127
+535
+0.8% +$31.2K 0.12% 204
2018
Q4 		$2.93M Buy
63,592
+10,013
+19% +$618K 0.09% 243
2018
Q3 		$4.13M Buy
53,579
+499
+0.9% +$40.1K 0.11% 210
2018
Q2 		$4.47M Buy
53,080
+33,643
+173% +$2.93M 0.12% 191
2018
Q1 		$1.59M Sell
19,437
-662
-3% -$51.2K 0.04% 455
2017
Q4 		$1.15M Sell
20,099
-1,346
-6% -$84.7K 0.03% 570
2017
Q3 		$1.43M Buy
+21,445
New +$1.29M 0.04% 490
2015
Q3 		– Sell
-2,000
Closed -$222K – 1347
2015
Q2 		$222K Buy
+2,000
New +$215K 0.01% 1244

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Oppenheimer & Co's AGIO Position: Q2 2020 in Review

Oppenheimer & Co sold out of Agios Pharmaceuticals (AGIO) in Q2 2020, closing a stake of 50,340 shares — an estimated $1.79M sold.

Oppenheimer & Co first reported a position in AGIO in Q2 2015 and held it in 12 quarters. The position peaked at $4.47M in Q2 2018. 217 funds tracked by Wall St. Rank hold AGIO as of Q2 2020.

  • Oppenheimer & Co reported no remaining Agios Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Oppenheimer & Co sold 50,340 Agios Pharmaceuticals shares in Q2 2020, an estimated $1.79M.
  • Oppenheimer & Co first reported a position in Agios Pharmaceuticals in Q2 2015 and held it in 12 quarters.
  • Oppenheimer & Co's Agios Pharmaceuticals position peaked at $4.47M in Q2 2018.
  • 217 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2020.

Based on Oppenheimer & Co's 13F filing for Q2 2020, filed 11 Aug 2020.